Community-Acquired Bacterial Pneumonia
FDA approves antibiotic to treat three bacterial infections
The FDA this week approved the antibiotic Zevtera for the treatment of three bacterial infections 17 years after it was first submitted to the agency.
Low-dose amoxicillin noninferior to higher dose for pediatric pneumonia
A lower dose of oral amoxicillin was noninferior to a higher dose in children with community-acquired pneumonia who were discharged from an ED or hospital ward, according to results of a 2x2 factorial, randomized clinical trial in JAMA.
Lefamulin a safe, effective alternative to moxifloxacin for unilobar, multilobar pneumonia
In a pooled analysis of the LEAP 1 and LEAP 2 trials, lefamulin was safe and its efficacy was comparable to that of moxifloxacin in patients with unilobar and multilobar community-acquired bacterial pneumonia.
FDA approves omadacycline oral regimen for community-acquired bacterial pneumonia
The FDA has approved omadacycline, an oral-only dosing regimen, for the treatment of community-acquired bacterial pneumonia, according to a press release from Paratek Pharmaceuticals.